Zealand Pharma A/S (OTCMKTS:ZLDPF) Rating Increased to Strong-Buy at BNP Paribas

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) was upgraded by analysts at BNP Paribas to a "strong-buy" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Separately, William Blair upgraded Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.

Zealand Pharma A/S Price Performance

ZLDPF opened at $57.75 on Tuesday. The business's fifty day moving average is $65.08 and its two-hundred day moving average is $80.85. The company has a debt-to-equity ratio of 0.03, a quick ratio of 25.07 and a current ratio of 25.10. The company has a market cap of $4.10 billion, a price-to-earnings ratio of -23.19 and a beta of 0.68. Zealand Pharma A/S has a one year low of $54.95 and a one year high of $141.74.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.10. The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $248.61 million. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. Analysts anticipate that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.